POSTER: MM-371 Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study

Autor: Bahlis, Nizar J., Samaras, Christy, Reece, Donna, Sebag, Michael, Matous, Jeffrey, Berdeja, Jesús G., Shustik, Jesse, Schiller, Gary J., Ganguly, Siddhartha, Song, Kevin, Seet, Christopher S., Acosta-Rivera, Mirelis, Quick, Donald, Anz, Bertrand, Fonseca, Gustavo, Liu, Hongjuan, Gentili, Christian, Siegel, David S.
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S225-S225
Databáze: ScienceDirect
Externí odkaz: